Invention Grant
- Patent Title: Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof
-
Application No.: US15963167Application Date: 2018-04-26
-
Publication No.: US10577415B2Publication Date: 2020-03-03
- Inventor: Robert Jan Benschop , Stephen John Demarest , Xiufeng Wu
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Robert L. Sharp
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/24 ; C07K16/18 ; A61K39/00

Abstract:
IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.
Public/Granted literature
- US20180319880A1 ANTI-CGRP/ANTI-IL-23 BISPECIFIC ANTIBODIES AND USES THEREOF Public/Granted day:2018-11-08
Information query